These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 22324304)

  • 1. Pemetrexed disodium in ovarian cancer treatment.
    Morotti M; Valenzano Menada M; Venturini PL; Mammoliti S; Ferrero S
    Expert Opin Investig Drugs; 2012 Apr; 21(4):437-49. PubMed ID: 22324304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The current state of pemetrexed in ovarian cancer.
    Miller RE; Banerjee S
    Expert Opin Investig Drugs; 2013 Sep; 22(9):1201-10. PubMed ID: 23899335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of a promising new agent--pemetrexed disodium.
    Paz-Ares L; Bezares S; Tabernero JM; Castellanos D; Cortes-Funes H
    Cancer; 2003 Apr; 97(8 Suppl):2056-63. PubMed ID: 12673697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemetrexed in advanced non-small-cell lung cancer.
    Fuld AD; Dragnev KH; Rigas JR
    Expert Opin Pharmacother; 2010 Jun; 11(8):1387-402. PubMed ID: 20446853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemetrexed: a novel antifolate agent enters clinical practice.
    Kut V; Patel JD; Argiris A
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):511-22. PubMed ID: 15270656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514).
    Jones RJ; Twelves CJ
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):13-22. PubMed ID: 12113062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging role of pemetrexed in ovarian cancer.
    Tomao F; Panici PB; Frati L; Tomao S
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1727-35. PubMed ID: 19954283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer.
    Sehouli J; Camara O; Mahner S; Bauknecht T; Lichtenegger W; Runnebaum I; Look K; Jaenicke F; Oskay-Oezcelik G
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):861-8. PubMed ID: 20054549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pemetrexed in advanced non-small cell lung cancer.
    Gridelli C; Maione P; Rossi A; Bareschino MA; Schettino C; Sacco PC; Zeppa R
    Expert Opin Drug Saf; 2011 Mar; 10(2):311-7. PubMed ID: 21261558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of Alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials.
    Hanauske AR
    Lung Cancer; 2004 Aug; 45 Suppl 1():S121-4. PubMed ID: 15261444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer.
    Vergote I; Calvert H; Kania M; Kaiser C; Zimmermann AH; Sehouli J
    Eur J Cancer; 2009 May; 45(8):1415-23. PubMed ID: 19168349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.
    Budde LS; Hanna NH
    Expert Rev Anticancer Ther; 2004 Jun; 4(3):361-8. PubMed ID: 15161435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pemetrexed therapy for malignant pleural mesothelioma.
    Puto K; Garey JS
    Ann Pharmacother; 2005 Apr; 39(4):678-83. PubMed ID: 15755794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
    J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of pemetrexed in breast cancer.
    Dittrich C
    Semin Oncol; 2006 Jun; 33(3 Suppl 9):S24-8. PubMed ID: 16797379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer.
    Scagliotti GV; Selvaggi G
    Clin Lung Cancer; 2008; 9 Suppl 3():S122-8. PubMed ID: 19419926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
    Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
    J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Update of pemetrexed in thoracic oncology].
    Brechot JM; Morère JF
    Bull Cancer; 2007; 94 Spec No Actualites():S139-41. PubMed ID: 17845984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
    Zhang YF; Chen ZW; Lu S
    Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.